Novartis reports data from trial of IgA nephropathy treatment
IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide
IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide
Aims to become a leading global partner for botanical extracts and natural actives in the beauty and personal care market
Empowering Research, Enhancing Proficiency is the theme of this year’s Homoeopathic Symposium
A game changing solution for the pharmaceutical industry
Wacker Biotech is a CDMO for the GMP-compliant production of active ingredients for the pharmaceutical industry
Highly effective preservation solutions ensuring the safety and protection of personal care products
These facilities are commissioned by Aurobindo's wholly own subsidiary: Lyfius Pharma Private Limited, Qule Pharma Private Limited, Eugia Steriles Private Limited and Auroactive Pharma Private Limited.
Utidelone has the ability to cross BBB due to its unique physicochemical characteristic and insusceptibility to P-glycoprotein-mediated efflux
For the treatment of stenotic lesions of arteriovenous fistula in the haemodialysis management of chronic renal failure
Subscribe To Our Newsletter & Stay Updated